Newly-Created Company, Bioxodes, Focused on Peptide Therapeutics from Natural Sources - June 2012
BELGIUM – Bioxodes, a new biotech start-up based in Belgium, today announced the completion of licensing discussions with the University of Brussels (ULB) in relation to a portfolio of patents relevant to the company’s emerging pipeline of naturally-derived peptides.
Bioxodes was founded to exploit the results of work conducted by Prof. Edmond Godfroid in collaboration with internationally-recognized academic groups which concentrates on establishing the molecular basis of host-parasite relationships.
Today’s announcement relates to a worldwide, exclusive licence in favour of the company. Financial terms were not disclosed.
Professor Edmond Godfroid’s work has been instrumental in identifying a range of naturally-derived molecules with therapeutic potential said: “I am delighted that our fledgling company has been able to secure the intellectual property which has arisen from my work. This means that we can now initiate the process of raising finance to progress development of the molecules towards proof-of-clinical concept.”
The company has established a business plan and is in the early stages of contacting potential investors to support the company’s first phase of growth.
The natural products the company is developing are relevant to a range of human conditions and diseases including pain, blood clotting and inflammation. The company’s lead product is Ir-CPI a first-in-class antithrombotic with the unprecedented property of inhibiting clotting at doses which do not cause bleeding. The market for an injectable form of such a molecule for use in hospitals is estimated to exceed $1bn annually. Earlier stage products include anti-inflammatory peptides relevant to a range of conditions including renal ischemia and chronic obstructive pulmonary disease.
Note to Editors
Research conducted by Prof. Edmond Godfroid (ULB) in collaboration with prestigious academic groups has established the molecular basis of the parasitic relationship a tick establishes with its vertebrate host. Ticks rank second only to mosquitoes as global vectors of disease. Prof. Edmond Godfroid’s research has focused on a particular tick species known as Ixodes ricinus, familiar to some as the carrier of Lyme disease. Ixodes ricinus is considered capable of infesting most terrestrial vertebrates in Europe. The tick feeds on the blood of its host following a bite. A particular characteristic of this meal is its extended duration of up to two weeks. This long meal involves no pain, blood clotting or inflammation. Scientists believe that such effects result from the presence of active principles in the saliva of the tick. Bioxodes controls the intellectual property relating to these active molecules and is developing a portfolio of products with a wide range of benefical healthcare applications in man. Professor Godfroid’s research was funded in large part by the Région Wallonne.